These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 28245575)

  • 1. Targeting Splicing in the Treatment of Human Disease.
    Suñé-Pou M; Prieto-Sánchez S; Boyero-Corral S; Moreno-Castro C; El Yousfi Y; Suñé-Negre JM; Hernández-Munain C; Suñé C
    Genes (Basel); 2017 Feb; 8(3):. PubMed ID: 28245575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting RNA splicing for disease therapy.
    Havens MA; Duelli DM; Hastings ML
    Wiley Interdiscip Rev RNA; 2013; 4(3):247-66. PubMed ID: 23512601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More than a messenger: Alternative splicing as a therapeutic target.
    Black AJ; Gamarra JR; Giudice J
    Biochim Biophys Acta Gene Regul Mech; 2019; 1862(11-12):194395. PubMed ID: 31271898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of pre-mRNA splicing by antisense oligonucleotides.
    Taylor JK; Dean NM
    Curr Opin Drug Discov Devel; 1999 Mar; 2(2):147-51. PubMed ID: 19649941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative Splicing: Expanding the Landscape of Cancer Biomarkers and Therapeutics.
    Bessa C; Matos P; Jordan P; Gonçalves V
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33261131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNA splicing manipulation: strategies to modify gene expression for a variety of therapeutic outcomes.
    Wilton SD; Fletcher S
    Curr Gene Ther; 2005 Oct; 5(5):467-83. PubMed ID: 16250888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics.
    Urbanski LM; Leclair N; Anczuków O
    Wiley Interdiscip Rev RNA; 2018 Jul; 9(4):e1476. PubMed ID: 29693319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional coupling of transcription and splicing.
    Montes M; Becerra S; Sánchez-Álvarez M; Suñé C
    Gene; 2012 Jun; 501(2):104-17. PubMed ID: 22537677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA splicing manipulation: strategies to modify gene expression for a variety of therapeutic outcomes.
    Wilton SD; Fletcher S
    Curr Gene Ther; 2011 Aug; 11(4):259-75. PubMed ID: 21453280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hallmarks of Splicing Defects in Cancer: Clinical Applications in the Era of Personalized Medicine.
    Rahman MA; Nasrin F; Bhattacharjee S; Nandi S
    Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32481522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA splicing: disease and therapy.
    Douglas AG; Wood MJ
    Brief Funct Genomics; 2011 May; 10(3):151-64. PubMed ID: 21628314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Splicing and neurodegeneration: Insights and mechanisms.
    Nik S; Bowman TV
    Wiley Interdiscip Rev RNA; 2019 Jul; 10(4):e1532. PubMed ID: 30895702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Splice-switching antisense oligonucleotides as therapeutic drugs.
    Havens MA; Hastings ML
    Nucleic Acids Res; 2016 Aug; 44(14):6549-63. PubMed ID: 27288447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative pre-mRNA splicing in digestive tract malignancy.
    Miura K; Fujibuchi W; Sasaki I
    Cancer Sci; 2011 Feb; 102(2):309-16. PubMed ID: 21134075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Splicing in the immune system: potential targets for therapeutic intervention by antisense-mediated alternative splicing.
    Mourich DV; Iversen PL
    Curr Opin Mol Ther; 2009 Apr; 11(2):124-32. PubMed ID: 19330718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptidic tools applied to redirect alternative splicing events.
    Nancy MM; Nora RM; Rebeca MC
    Peptides; 2015 May; 67():1-11. PubMed ID: 25748022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inherited Retinal Disease Therapies Targeting Precursor Messenger Ribonucleic Acid.
    Huang D; Fletcher S; Wilton SD; Palmer N; McLenachan S; Mackey DA; Chen FK
    Vision (Basel); 2017 Sep; 1(3):. PubMed ID: 31740647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From General Aberrant Alternative Splicing in Cancers and Its Therapeutic Application to the Discovery of an Oncogenic DMTF1 Isoform.
    Tian N; Li J; Shi J; Sui G
    Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28257090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense oligonucleotide-based therapies for diseases caused by pre-mRNA processing defects.
    Rigo F; Seth PP; Bennett CF
    Adv Exp Med Biol; 2014; 825():303-52. PubMed ID: 25201110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer-Associated Perturbations in Alternative Pre-messenger RNA Splicing.
    Shkreta L; Bell B; Revil T; Venables JP; Prinos P; Elela SA; Chabot B
    Cancer Treat Res; 2013; 158():41-94. PubMed ID: 24222354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.